Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology

Jessica Tao, Alison M. Schram, David M. Hyman

Research output: Contribution to journalArticle

Abstract

Understanding a tumor's detailed molecular profile has become increasingly necessary to deliver the standard of care for patients with advanced cancer. Innovations in both tumor genomic sequencing technology and the development of drugs that target molecular alterations have fueled recent gains in genome-driven oncology care. "Basket studies," or histology-agnostic clinical trials in genomically selected patients, represent one important research tool to continue making progress in this field. We review key aspects of genome-driven oncology care, including the purpose and utility of basket studies, biostatistical considerations in trial design, genomic knowledgebase development, and patient matching and enrollment models, which are critical for translating our genomic knowledge into clinically meaningful outcomes.

Original languageEnglish (US)
Pages (from-to)319-331
Number of pages13
JournalAnnual review of medicine
Volume69
DOIs
StatePublished - Jan 29 2018
Externally publishedYes

Fingerprint

Oncology
Tumors
Genes
Clinical Trials
Genome
Histology
Neoplasms
Knowledge Bases
Innovation
Standard of Care
Pharmaceutical Preparations
Technology
Research

Keywords

  • Basket study
  • Basket trial
  • Genome-driven oncology
  • Knowledgebase
  • Precision medicine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Basket Studies : Redefining Clinical Trials in the Era of Genome-Driven Oncology. / Tao, Jessica; Schram, Alison M.; Hyman, David M.

In: Annual review of medicine, Vol. 69, 29.01.2018, p. 319-331.

Research output: Contribution to journalArticle

@article{e5d297d1f9ab49b79ab94c3e14f2efad,
title = "Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology",
abstract = "Understanding a tumor's detailed molecular profile has become increasingly necessary to deliver the standard of care for patients with advanced cancer. Innovations in both tumor genomic sequencing technology and the development of drugs that target molecular alterations have fueled recent gains in genome-driven oncology care. {"}Basket studies,{"} or histology-agnostic clinical trials in genomically selected patients, represent one important research tool to continue making progress in this field. We review key aspects of genome-driven oncology care, including the purpose and utility of basket studies, biostatistical considerations in trial design, genomic knowledgebase development, and patient matching and enrollment models, which are critical for translating our genomic knowledge into clinically meaningful outcomes.",
keywords = "Basket study, Basket trial, Genome-driven oncology, Knowledgebase, Precision medicine",
author = "Jessica Tao and Schram, {Alison M.} and Hyman, {David M.}",
year = "2018",
month = "1",
day = "29",
doi = "10.1146/annurev-med-062016-050343",
language = "English (US)",
volume = "69",
pages = "319--331",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Basket Studies

T2 - Redefining Clinical Trials in the Era of Genome-Driven Oncology

AU - Tao, Jessica

AU - Schram, Alison M.

AU - Hyman, David M.

PY - 2018/1/29

Y1 - 2018/1/29

N2 - Understanding a tumor's detailed molecular profile has become increasingly necessary to deliver the standard of care for patients with advanced cancer. Innovations in both tumor genomic sequencing technology and the development of drugs that target molecular alterations have fueled recent gains in genome-driven oncology care. "Basket studies," or histology-agnostic clinical trials in genomically selected patients, represent one important research tool to continue making progress in this field. We review key aspects of genome-driven oncology care, including the purpose and utility of basket studies, biostatistical considerations in trial design, genomic knowledgebase development, and patient matching and enrollment models, which are critical for translating our genomic knowledge into clinically meaningful outcomes.

AB - Understanding a tumor's detailed molecular profile has become increasingly necessary to deliver the standard of care for patients with advanced cancer. Innovations in both tumor genomic sequencing technology and the development of drugs that target molecular alterations have fueled recent gains in genome-driven oncology care. "Basket studies," or histology-agnostic clinical trials in genomically selected patients, represent one important research tool to continue making progress in this field. We review key aspects of genome-driven oncology care, including the purpose and utility of basket studies, biostatistical considerations in trial design, genomic knowledgebase development, and patient matching and enrollment models, which are critical for translating our genomic knowledge into clinically meaningful outcomes.

KW - Basket study

KW - Basket trial

KW - Genome-driven oncology

KW - Knowledgebase

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85041716945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041716945&partnerID=8YFLogxK

U2 - 10.1146/annurev-med-062016-050343

DO - 10.1146/annurev-med-062016-050343

M3 - Article

C2 - 29120700

AN - SCOPUS:85041716945

VL - 69

SP - 319

EP - 331

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -